发明名称 BETA-AMYLOID-ANALOGUE - T-CEL EPITOP VACCINE
摘要 Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (Abeta). Immunization is preferably effected by administration of analogues of autologous APP or Abeta, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous Abeta which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against APP or Abeta and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.
申请公布号 KR20090074830(A) 申请公布日期 2009.07.07
申请号 KR20097013183 申请日期 2002.08.20
申请人 H. LUNDBECK A/S 发明人 RASMUSSEN PETER BIRK;JENSEN MARTIN ROLAND;NIELSEN KLAUS GREGORIUS;KOEFOED PETER;DEGAN FLORENCE DAL
分类号 A61K39/395;C12N15/09;A61K;A61K35/74;A61K35/76;A61K38/00;A61K39/00;A61K39/02;A61K39/08;A61K39/10;A61K39/12;A61K39/385;A61K39/39;A61K45/06;A61K48/00;A61P;A61P3/10;A61P25/00;A61P25/14;A61P25/16;A61P25/28;C07K;C07K14/47;C07K19/00;C12N1/15;C12N1/19;C12N1/21;C12N5/10 主分类号 A61K39/395
代理机构 代理人
主权项
地址